HRP20140765T1 - Vektori i konstrukti za prijenos antigena gripe - Google Patents

Vektori i konstrukti za prijenos antigena gripe Download PDF

Info

Publication number
HRP20140765T1
HRP20140765T1 HRP20140765AT HRP20140765T HRP20140765T1 HR P20140765 T1 HRP20140765 T1 HR P20140765T1 HR P20140765A T HRP20140765A T HR P20140765AT HR P20140765 T HRP20140765 T HR P20140765T HR P20140765 T1 HRP20140765 T1 HR P20140765T1
Authority
HR
Croatia
Prior art keywords
construct
pharmaceutical preparation
influenza
preparation according
derivatives
Prior art date
Application number
HRP20140765AT
Other languages
English (en)
Inventor
Dominique Bonnet
Carlton B. Brown
Bertrand Georges
Philip J. Sizer
Original Assignee
Immune Targeting Systems (Its) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Targeting Systems (Its) Limited filed Critical Immune Targeting Systems (Its) Limited
Publication of HRP20140765T1 publication Critical patent/HRP20140765T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (15)

1. Konstrukt fluorugljicnog vektora i antigena, slijedeće strukture CmFn-CyHx-(Sp)-R ili njihove derivate, pri čemu je m = 3 do 30, n <2m +1, y = 0 do 15, X <= 2Y, (m + y) = 3-30, Sp je dodatna kemijska razdvajajuća skupina, a R je peptid virusa gripe HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK (SEQ IDNO: 1) ili njegov homolog koji ima najmanje 90% identiteta od SEQ ID NO: 1.
2. Farmaceutski pripravak, naznačen time, da sadrži konstrukt fluorugljičnog vektora i antigena prema zahtjevu 1 zajedno s jednim ili više farmaceutski prihvatljivih nosača, pomoćnih tvari, razrjeđivača ili pomoćnih sredstava.
3. Farmaceutski pripravak prema zahtjevu 2, naznačen time, da je formuliran za parenteralnu, oralnu, očnu, rektalnu, nazalnu, transdermalnu, lokalnu ili vaginalnu primjenu.
4. Farmaceutski pripravak prema zahtjevu 2, naznačen time, da je obliku tekućine, krutine, emulzija, aerosola ili plina.
5. Farmaceutski pripravak prema zahtjevu 2, koji sadrži pomoćno sredstvo naznačen time, da se spomenuto pomoćno sredstvo odabire iz skupina: (1) prirodni ili sintetski dobivene prerađevine prirodnih sastojaka bakterija, kao što su Freundov adjuvans i njegovi derivati, derivati muramildipeptida (MDP), CpG, monofosforil lipid A; (2) pomoćna sredstva ili sredstva za pojačavanje, kao što su saponini, aluminijeve soli i citokini; (3) adjuvansi ulje-u-vodi, adjuvansi voda-u-ulju, imunostimulirajuci kompleks (ISKOMS), liposomi, formulirane nano i mikro-čestice; i (4) bakterijski toksini i toksoidi.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 5, naznačen time, da nadalje obuhvaća više konstrukcija fluorugljičnog vektora i antigena strukture CmFn-Cy-Hx-(Sp)-R ili njihove derivate, pri čemu je m = 3 do 30, n <= 2m +1, y = 0 do 15, x <= 2y, (m + y) = 3-30, Sp je dodatna kemijska razdvajajuća skupina, a R je peptid virusa gripe.
7. Farmaceutski pripravak, naznačen time, da sadrži najmanje dva konstrukta vektorantigen strukture CmFn-Cy-Hx-(Sp)-R ili njihove derivate, pri čemu je m = 3 do 30, n <= 2m + 1, y = 0 do 15, X <= 2y, (m + y) = 3 - 30, Sp je dodatna razdvajajuća kemijska skupina, a R je peptid virusa gripe, prvi konstrukt sadrži peptidni slijed gripe: HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK i drugi konstrukt sadrži peptidni slijed gripe: YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 7, naznačen time, da sadrži osam vektor-antigen konstrukcija koji obuhvaćaju sljedeće peptidne sljedove gripe: Konstrukt 1 HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK Konstrukt 2 VAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQG Konstrukt 3 YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE Konstrukt 4 APIMFSNKMARLGKGYMFESKRMKLRTQIPAEMLA Konstrukt 5 SPGMMMGMFNMLSTVLGVSILNLGQKKYTKTTY Konstrukt 6 KKKSYINKTGTFEFTSFFYRYGFVANFSMELPSFG Konstrukt 7 DQVRESRNPGNAEIEDLIFLARSALILRGSVAHKS Konstrukt 8 DLEALMEWLKTRPILSPLTKGILGFVFTLTVPSER
9. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 2 do 8, naznačen time, da je namijenjen za uporabu u postupku liječenja ili za cijepljenje protiv gripe.
10. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 2 do 8, naznačen time, da je namijenjen za uporabu u postupku za stimuliranje imunog odgovora kod čovjeka ili životinje.
11. Farmaceutski sastav prema zahtjevu 9 ili 10 za uporabu u skladu sa zahtjevom 9 ili 10 naznačen time, da se upotrebljava u kombinaciji s terapijom protiv gripe.
12. Farmaceutski pripravak prema zahtjevu 11 za uporabu u skladu sa zahtjevom 11, naznačen time, da se za liječenje gripe koristi neuraminidaza inhibitor.
13. Farmaceutski sastav prema zahtjevu 9 ili 10 za uporabu u skladu sa zahtjevom 9 ili 10, naznačen time, da se primjenjuje u kombinaciji sa cjepivom protiv gripe koje sadrži hemaglutinin, istodobnom ili odvojenom primjenom.
14. Postupak priprave terapijskog ili profilaktičkog farmaceutskog proizvoda, naznačen time, da obuhvaća kombiniranje fluorugljičnog konstrukta prema zahtjevu 1, s jednim ili više farmaceutski prihvatljivih nosaca, pomoćnih tvari, razrjeđivača ili pomoćnih tvari.
15. Uporaba farmaceutskog pripravka prema bilo kojem od patentnih zahtjeva 2 do 8, naznačena time, da je namijenjena pripravi lijeka za liječenje ili prevenciju od gripe ili njezinih simptoma.
HRP20140765AT 2007-08-31 2014-08-14 Vektori i konstrukti za prijenos antigena gripe HRP20140765T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716992.3A GB0716992D0 (en) 2007-08-31 2007-08-31 Influenza antigen delivery vectors and constructs
PCT/GB2008/002930 WO2009027688A1 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs

Publications (1)

Publication Number Publication Date
HRP20140765T1 true HRP20140765T1 (hr) 2014-09-12

Family

ID=38617093

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140765AT HRP20140765T1 (hr) 2007-08-31 2014-08-14 Vektori i konstrukti za prijenos antigena gripe

Country Status (23)

Country Link
US (4) US8642531B2 (hr)
EP (2) EP2762164B1 (hr)
JP (5) JP5756630B2 (hr)
KR (3) KR101665141B1 (hr)
CN (1) CN101827607A (hr)
AR (1) AR068507A1 (hr)
AU (1) AU2008291974B2 (hr)
BR (1) BRPI0815836A2 (hr)
CA (1) CA2697729C (hr)
CL (1) CL2008002559A1 (hr)
CY (1) CY1115598T1 (hr)
DK (2) DK2190474T3 (hr)
EA (1) EA018765B1 (hr)
ES (2) ES2488941T3 (hr)
GB (2) GB0716992D0 (hr)
HK (1) HK1144153A1 (hr)
HR (1) HRP20140765T1 (hr)
MX (1) MX2010002335A (hr)
PL (1) PL2190474T3 (hr)
PT (1) PT2190474E (hr)
SI (1) SI2190474T1 (hr)
TW (2) TWI469790B (hr)
WO (1) WO2009027688A1 (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
CA2807043A1 (en) 2010-08-03 2012-02-09 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
EP2646459B1 (en) * 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
WO2013138259A2 (en) 2012-03-13 2013-09-19 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
US9771395B2 (en) 2014-03-21 2017-09-26 University Of Washington Enhanced influenza hemagglutinin binders
WO2015157189A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
JP6103547B2 (ja) * 2015-01-09 2017-03-29 三菱電機株式会社 電子基板ユニット
AU2016354590B2 (en) 2015-11-13 2023-11-23 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3257864A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Metabolically stable spexin peptide analogs
EP3257863A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Flourous metabolically stable peptide analogs
CN110035765B (zh) 2016-10-05 2024-04-02 Pds生物科技公司 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法
US11111277B2 (en) 2016-12-28 2021-09-07 Invvax, Inc. Influenza vaccines
WO2019046901A1 (en) * 2017-09-08 2019-03-14 The University Of Melbourne METHODS AND COMPOSITIONS FOR PREVENTING INFLUENZA INFECTION
US20210236623A1 (en) * 2018-04-04 2021-08-05 Altimmune, Inc. T-cell inducing vaccine composition combination and uses thereof
JP7037994B2 (ja) 2018-04-11 2022-03-17 株式会社シマノ 制御装置、人力駆動車、および制御方法
CN110772635B (zh) * 2019-11-11 2023-01-31 扬州大学 流感病毒小体包被的仿生纳米疫苗及其制备方法
WO2022005893A1 (en) * 2020-06-29 2022-01-06 Seqirus UK Limited Adaptive vaccine stockpile
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065141A (en) 1960-08-24 1962-11-20 Albert E Gessler Separation of nucleoproteins and nucleic acids from aqueous protein mixtures
GB1193378A (en) 1967-04-11 1970-05-28 Rand Dev Corp Cancer Antigen Complexes
US3843443A (en) 1973-03-30 1974-10-22 J Fishman Polypeptide materials bound to fluorocarbon polymers
US4332787A (en) 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
US4689398A (en) 1984-06-20 1987-08-25 Ortho Diagnostic Systems Inc. HTLV test using synthetic peptides
US4716102A (en) 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
ATE82985T1 (de) 1986-06-12 1992-12-15 Behringwerke Ag Strukturelles phosphoprotein (pp 150) des menschlichen cytomegalovirus, seine herstellung und verwendung.
DE3784592T2 (de) 1986-08-07 1993-09-23 Minnesota Mining & Mfg Stabile, biologisch-aktive, fluorchemische emulsionen.
US4954444A (en) 1987-03-02 1990-09-04 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5021551A (en) 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
WO1991017187A2 (en) 1990-04-18 1991-11-14 The Regents Of The University Of California A 35kD TUMOR ASSOCIATED PROTEIN ANTIGEN: USES AND METHODS OF DETECTION
BR9106879A (pt) 1990-09-25 1993-07-20 Cantab Pharma Res Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
JPH07500483A (ja) 1991-03-14 1995-01-19 ブリティッシュ・テクノロジー・グループ・ユーエスエイ・インコーポレーテッド 組換え体抗コクシジアワクチン
EP0503203A1 (en) 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Novel thrombin inhibitors
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
CA2188432C (en) 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
GB9420146D0 (en) 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US6548046B1 (en) 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6069232A (en) 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6121123A (en) 1997-09-05 2000-09-19 Advanced Micro Devices, Inc. Gate pattern formation using a BARC as a hardmask
AU1117999A (en) 1997-10-24 1999-05-17 Alliance Pharmaceutical Corporation Amelioration of ischemic damage using synthetic oxygen carriers
JP2002507397A (ja) 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
RU2218175C2 (ru) * 2001-03-06 2003-12-10 Научно-исследовательский институт по изучению лепры Способ стимуляции образования антител при иммунизации лабораторных животных
WO2002072627A2 (en) 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
US20050013826A1 (en) 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
DE112005003343B4 (de) 2004-12-30 2011-05-19 Intel Corporation, Santa Clara Mechanismus für eine befehlssatzbasierte Threadausführung an mehreren Befehlsablaufsteuerungen
FR2883563B1 (fr) 2005-03-24 2007-06-01 Ts Pharma Sarl Nouveaux vecteurs cationiques bolaformes hemifluorocarbones et leurs applications
WO2007085969A2 (en) * 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP1982992B1 (en) * 2006-02-07 2010-10-27 NEC Corporation Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation

Also Published As

Publication number Publication date
WO2009027688A1 (en) 2009-03-05
KR20100067094A (ko) 2010-06-18
CA2697729A1 (en) 2009-03-05
KR101736897B1 (ko) 2017-05-17
US9446143B2 (en) 2016-09-20
US20140234356A1 (en) 2014-08-21
GB201005395D0 (en) 2010-05-12
TW201345551A (zh) 2013-11-16
US10155049B2 (en) 2018-12-18
CY1115598T1 (el) 2017-01-04
US8642531B2 (en) 2014-02-04
CL2008002559A1 (es) 2009-06-26
JP2013241414A (ja) 2013-12-05
EP2190474A1 (en) 2010-06-02
EA018765B1 (ru) 2013-10-30
CN101827607A (zh) 2010-09-08
JP5756630B2 (ja) 2015-07-29
AR068507A1 (es) 2009-11-18
GB2465733B (en) 2010-12-01
EP2190474B1 (en) 2014-05-14
KR20150074182A (ko) 2015-07-01
AU2008291974B2 (en) 2012-06-28
EP2762164A1 (en) 2014-08-06
SI2190474T1 (sl) 2014-09-30
JP6826027B2 (ja) 2021-02-03
US20190142951A1 (en) 2019-05-16
US20090191233A1 (en) 2009-07-30
AU2008291974A1 (en) 2009-03-05
TWI469790B (zh) 2015-01-21
DK2190474T3 (da) 2014-08-18
ES2741729T3 (es) 2020-02-12
TW200930400A (en) 2009-07-16
BRPI0815836A2 (pt) 2015-03-03
ES2488941T3 (es) 2014-09-01
MX2010002335A (es) 2010-08-10
HK1144153A1 (en) 2011-01-28
JP2018076355A (ja) 2018-05-17
CA2697729C (en) 2016-07-26
US20210316000A9 (en) 2021-10-14
PT2190474E (pt) 2014-08-29
GB2465733A (en) 2010-06-02
PL2190474T3 (pl) 2014-11-28
JP2016155829A (ja) 2016-09-01
GB0716992D0 (en) 2007-10-10
EA201070329A1 (ru) 2010-10-29
KR101665141B1 (ko) 2016-10-25
JP2021001216A (ja) 2021-01-07
EP2762164B1 (en) 2019-05-08
US20170049898A1 (en) 2017-02-23
JP2010537961A (ja) 2010-12-09
DK2762164T3 (da) 2019-08-12
KR20170001729A (ko) 2017-01-04

Similar Documents

Publication Publication Date Title
HRP20140765T1 (hr) Vektori i konstrukti za prijenos antigena gripe
JP2010537961A5 (hr)
AU646257B2 (en) Oral vaccine comprising antigen surface-associated with red blood cells
Jiao et al. Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
Hirabayashi et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination
Kopecky-Bromberg et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine
US6391318B1 (en) Vaccine compositions including chitosan for intranasal administration and use thereof
US9603920B2 (en) Compositions and methods for treating influenza
JP2018193395A (ja) 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
KR20070008309A (ko) 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
JP2014520807A5 (hr)
US20110223198A1 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
CA2674042A1 (en) Non-specific immunostimulating agents
CA2792369A1 (en) Vaccines for influenza
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
Shim et al. Nontoxic outer membrane vesicles efficiently increase the efficacy of an influenza vaccine in mice and ferrets
AU2009232503B2 (en) Anti-infective agents and uses thereof
US20050152919A1 (en) Measles subunit vaccine
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
Van Slooten et al. Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines
US20230270839A1 (en) Vaccine compositions
US5882649A (en) Oral vaccine comprising antigen surface-associated with red blood cells
JP2010529166A (ja) 皮内インフルエンザワクチン
JP2010529166A5 (hr)